{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:42:21Z","timestamp":1792644141417,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T00:00:00Z","timestamp":1699401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T00:00:00Z","timestamp":1699401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s00262-023-03565-6","type":"journal-article","created":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T16:02:23Z","timestamp":1699459343000},"page":"4309-4322","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Chronological interplay, clinical features, and treatments among patients with cancer and primary Sj\u00f6gren\u2019s syndrome"],"prefix":"10.1007","volume":"72","author":[{"given":"Philine","family":"Witkowski Durand Viel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Morel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Jacot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Jorgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Riviere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre Thibault Jacques","family":"Maria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Rigau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Le Quellec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radjiv","family":"Goulabchand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7673-2561","authenticated-orcid":false,"given":"Philippe","family":"Guilpain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,8]]},"reference":[{"key":"3565_CR1","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1080\/03009740310004676","volume":"33","author":"S Bowman","year":"2004","unstructured":"Bowman S, Ibrahim G, Holmes G et al (2004) Estimating the prevalence among Caucasian women of primary Sj\u00f6gren\u2019s syndrome in two general practices in Birmingham, UK. Scand J Rheumatol 33:39\u201343. https:\/\/doi.org\/10.1080\/03009740310004676","journal-title":"Scand J Rheumatol"},{"key":"3565_CR2","doi-asserted-by":"publisher","first-page":"247","DOI":"10.2147\/CLEP.S47399","volume":"6","author":"A Shahane","year":"2014","unstructured":"Shahane A, Patel R (2014) The epidemiology of Sj\u00f6gren\u2019s syndrome. Clin Epidemiol 6:247. https:\/\/doi.org\/10.2147\/CLEP.S47399","journal-title":"Clin Epidemiol"},{"key":"3565_CR3","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1007\/s00296-019-04433-2","volume":"39","author":"M Brom","year":"2019","unstructured":"Brom M, Moyano S, Gandino IJ et al (2019) Incidence of cancer in a cohort of patients with primary Sj\u00f6gren syndrome in Argentina. Rheumatol Int 39:1697\u20131702. https:\/\/doi.org\/10.1007\/s00296-019-04433-2","journal-title":"Rheumatol Int"},{"key":"3565_CR4","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.191027","author":"L-H Wang","year":"2020","unstructured":"Wang L-H, Wang W-M, Lin C-Y et al (2020) Bidirectional relationship between primary Sj\u00f6gren\u2019s syndrome and Non-Hodgkin\u2019s lymphoma: a nationwide population-based study. J Rheumatol Jrheum. https:\/\/doi.org\/10.3899\/jrheum.191027","journal-title":"J Rheumatol Jrheum"},{"key":"3565_CR5","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1136\/ard.2005.041186","volume":"65","author":"E Theander","year":"2006","unstructured":"Theander E, Henriksson G, Ljungberg O et al (2006) Lymphoma and other malignancies in primary Sj\u00f6gren\u2019s syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 65:796\u2013803. https:\/\/doi.org\/10.1136\/ard.2005.041186","journal-title":"Ann Rheum Dis"},{"key":"3565_CR6","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1136\/annrheumdis-2011-200402","volume":"71","author":"M-Y Weng","year":"2012","unstructured":"Weng M-Y, Huang Y-T, Liu M-F, Lu T-H (2012) Incidence of cancer in a nationwide population cohort of 7852 patients with primary Sj\u00f6gren\u2019s syndrome in Taiwan. Ann Rheum Dis 71:524\u2013527. https:\/\/doi.org\/10.1136\/annrheumdis-2011-200402","journal-title":"Ann Rheum Dis"},{"key":"3565_CR7","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1136\/annrheumdis-2013-203305","volume":"73","author":"Y Liang","year":"2014","unstructured":"Liang Y, Yang Z, Qin B, Zhong R (2014) Primary Sjogren\u2019s syndrome and malignancy risk: a systematic review and meta-analysis. Ann Rheum Dis 73:1151\u20131156. https:\/\/doi.org\/10.1136\/annrheumdis-2013-203305","journal-title":"Ann Rheum Dis"},{"key":"3565_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-017-0464-5","volume":"10","author":"P Brito-Zer\u00f3n","year":"2017","unstructured":"Brito-Zer\u00f3n P, Kostov B, Fraile G et al (2017) Characterization and risk estimate of cancer in patients with primary Sj\u00f6gren syndrome. J Hematol Oncol 10:1\u201312. https:\/\/doi.org\/10.1186\/s13045-017-0464-5","journal-title":"J Hematol Oncol"},{"key":"3565_CR9","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ygyno.2012.07.100","volume":"127","author":"K Hemminki","year":"2012","unstructured":"Hemminki K, Liu X, Ji J et al (2012) Effect of autoimmune diseases on risk and survival in female cancers. Gynecol Oncol 127:180\u2013185. https:\/\/doi.org\/10.1016\/j.ygyno.2012.07.100","journal-title":"Gynecol Oncol"},{"key":"3565_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102987","volume":"20","author":"R Goulabchand","year":"2021","unstructured":"Goulabchand R, Malafaye N, Jacot W et al (2021) Cancer incidence in primary Sj\u00f6gren\u2019s syndrome: data from the french hospitalization database. Autoimmun Rev 20:102987. https:\/\/doi.org\/10.1016\/j.autrev.2021.102987","journal-title":"Autoimmun Rev"},{"key":"3565_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2018.03112","volume":"9","author":"ATJ Maria","year":"2019","unstructured":"Maria ATJ, Partouche L, Goulabchand R et al (2019) Intriguing relationships between cancer and systemic sclerosis: role of the immune system and other contributors. Front Immunol 9:1\u201314. https:\/\/doi.org\/10.3389\/fimmu.2018.03112","journal-title":"Front Immunol"},{"key":"3565_CR12","doi-asserted-by":"publisher","first-page":"853","DOI":"10.3390\/jcm9030853","volume":"9","author":"L Partouche","year":"2020","unstructured":"Partouche L, Goulabchand R, Maria ATJ et al (2020) Biphasic temporal relationship between cancers and systemic sclerosis: a clinical series from montpellier university hospital and review of the literature. J Clin Med 9:853. https:\/\/doi.org\/10.3390\/jcm9030853","journal-title":"J Clin Med"},{"key":"3565_CR13","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.autrev.2017.07.022","volume":"16","author":"E Giat","year":"2017","unstructured":"Giat E, Ehrenfeld M, Shoenfeld Y (2017) Cancer and autoimmune diseases. Autoimmun Rev 16:1049\u20131057. https:\/\/doi.org\/10.1016\/j.autrev.2017.07.022","journal-title":"Autoimmun Rev"},{"key":"3565_CR14","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/art.39859","volume":"69","author":"CH Shiboski","year":"2017","unstructured":"Shiboski CH, Shiboski SC, Seror R et al (2017) 2016 American College of Rheumatology\/European league against rheumatism classification criteria for primary Sj\u00f6gren\u2019s syndrome: a consensus and data-driven methodology involving three international patient cohorts. Arthritis Rheumatol 69:35\u201345. https:\/\/doi.org\/10.1002\/art.39859","journal-title":"Arthritis Rheumatol"},{"key":"3565_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2014-000022","author":"R Seror","year":"2015","unstructured":"Seror R, Bowman SJ, Brito-Zeron P et al (2015) EULAR Sj\u00f6gren\u2019s syndrome disease activity index (ESSDAI): a user guide. RMD Open. https:\/\/doi.org\/10.1136\/rmdopen-2014-000022","journal-title":"RMD Open"},{"key":"3565_CR16","first-page":"S00","volume":"38","author":"JK Ahn","year":"2020","unstructured":"Ahn JK, Hwang J, Seo GH (2020) Risk of non-Hodgkin\u2019s lymphoma and thyroid cancer in primary Sj\u00f6gren\u2019s syndrome measured using the Korean Health Insurance Claims Database. Clin Exp Rheumatol 38:S00","journal-title":"Clin Exp Rheumatol"},{"key":"3565_CR17","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1080\/03009742.2019.1696403","volume":"49","author":"L Vasaitis","year":"2020","unstructured":"Vasaitis L, Nordmark G, Theander E et al (2020) Population-based study of patients with primary Sj\u00f6gren\u2019s syndrome and lymphoma: lymphoma subtypes, clinical characteristics, and gender differences. Scand J Rheumatol 49:225\u2013232. https:\/\/doi.org\/10.1080\/03009742.2019.1696403","journal-title":"Scand J Rheumatol"},{"key":"3565_CR18","doi-asserted-by":"publisher","first-page":"3226","DOI":"10.1002\/art.39315","volume":"67","author":"G Nocturne","year":"2015","unstructured":"Nocturne G, Seror R, Fogel O et al (2015) CXCL13 and CCL11 serum levels and lymphoma and disease activity in primary Sj\u00f6gren\u2019s syndrome. Arthritis Rheumatol 67:3226\u20133233. https:\/\/doi.org\/10.1002\/art.39315","journal-title":"Arthritis Rheumatol"},{"key":"3565_CR19","doi-asserted-by":"publisher","first-page":"3513","DOI":"10.1093\/rheumatology\/kez052","volume":"60","author":"G Nocturne","year":"2021","unstructured":"Nocturne G, Pontarini E, Bombardieri M, Mariette X (2021) Lymphomas complicating primary Sj\u00f6gren\u2019s syndrome: from autoimmunity to lymphoma. Rheumatology 60:3513\u20133521. https:\/\/doi.org\/10.1093\/rheumatology\/kez052","journal-title":"Rheumatology"},{"key":"3565_CR20","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nrrheum.2018.1","volume":"14","author":"G Nocturne","year":"2018","unstructured":"Nocturne G, Mariette X (2018) B cells in the pathogenesis of primary Sj\u00f6gren syndrome. Nat Rev Rheumatol 14:133\u2013145. https:\/\/doi.org\/10.1038\/nrrheum.2018.1","journal-title":"Nat Rev Rheumatol"},{"key":"3565_CR21","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.autrev.2018.08.007","volume":"18","author":"AV Goules","year":"2019","unstructured":"Goules AV, Tzioufas AG (2019) Lymphomagenesis in Sj\u00f6gren\u2019s syndrome: predictive biomarkers towards precision medicine. Autoimmun Rev 18:137\u2013143. https:\/\/doi.org\/10.1016\/j.autrev.2018.08.007","journal-title":"Autoimmun Rev"},{"key":"3565_CR22","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1177\/0961203319857132","volume":"28","author":"S Retamozo","year":"2019","unstructured":"Retamozo S, Brito-Zer\u00f3n P, Ramos-Casals M (2019) Prognostic markers of lymphoma development in primary Sj\u00f6gren syndrome. Lupus 28:923\u2013936. https:\/\/doi.org\/10.1177\/0961203319857132","journal-title":"Lupus"},{"key":"3565_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0222860","volume":"14","author":"HH Chen","year":"2019","unstructured":"Chen HH, Lin CH, Chen DY et al (2019) Risk of major autoimmune diseases in female breast cancer patients: a nationwide, population-based cohort study. PLoS ONE 14:1\u20139. https:\/\/doi.org\/10.1371\/journal.pone.0222860","journal-title":"PLoS ONE"},{"key":"3565_CR24","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1007\/s12026-016-8830-x","volume":"65","author":"R Goulabchand","year":"2017","unstructured":"Goulabchand R, Hafidi A, Millet I et al (2017) Mastitis associated with Sj\u00f6gren\u2019s syndrome: a series of nine cases. Immunol Res 65:218\u2013229. https:\/\/doi.org\/10.1007\/s12026-016-8830-x","journal-title":"Immunol Res"},{"key":"3565_CR25","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/s41584-018-0074-9","volume":"14","author":"LH Calabrese","year":"2018","unstructured":"Calabrese LH, Calabrese C, Cappelli LC (2018) Rheumatic immune-related adverse events from cancer immunotherapy. Nat Rev Rheumatol 14:569\u2013579. https:\/\/doi.org\/10.1038\/s41584-018-0074-9","journal-title":"Nat Rev Rheumatol"},{"key":"3565_CR26","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1007\/s00296-017-3715-4","volume":"37","author":"EJ ter Borg","year":"2017","unstructured":"ter Borg EJ, Kelder JC (2017) Development of new extra-glandular manifestations or associated auto-immune diseases after establishing the diagnosis of primary Sj\u00f6gren\u2019s syndrome: a long-term study of the Antonius Nieuwegein Sj\u00f6gren (ANS) cohort. Rheumatol Int 37:1153\u20131158. https:\/\/doi.org\/10.1007\/s00296-017-3715-4","journal-title":"Rheumatol Int"},{"key":"3565_CR27","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ejca.2017.05.032","volume":"82","author":"S Le Burel","year":"2017","unstructured":"Le Burel S, Champiat S, Mateus C et al (2017) Prevalence of immune-related systemic adverse events in patients treated with anti-programmed cell death 1\/anti-programmed cell death-ligand 1 agents: a single-centre pharmacovigilance database analysis. Eur J Cancer 82:34\u201344. https:\/\/doi.org\/10.1016\/j.ejca.2017.05.032","journal-title":"Eur J Cancer"},{"key":"3565_CR28","first-page":"S114","volume":"37","author":"M Ramos-Casals","year":"2019","unstructured":"Ramos-Casals M, Maria A, Su\u00e1rez-Almazor ME et al (2019) Sicca\/Sj\u00f6gren\u2019s syndrome triggered by PD-1\/PD-L1 checkpoint inhibitors. Data from the international immunocancer registry (ICIR). Clin Exp Rheumatol 37:S114\u2013S122","journal-title":"Clin Exp Rheumatol"},{"key":"3565_CR29","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1634\/theoncologist.2018-0823","volume":"24","author":"BM Warner","year":"2019","unstructured":"Warner BM, Baer AN, Lipson EJ et al (2019) Sicca syndrome associated with immune checkpoint inhibitor therapy. Oncologist 24:1259\u20131269. https:\/\/doi.org\/10.1634\/theoncologist.2018-0823","journal-title":"Oncologist"},{"key":"3565_CR30","doi-asserted-by":"publisher","first-page":"e391","DOI":"10.1634\/theoncologist.2019-0467","volume":"25","author":"A Ortiz Brugu\u00e9s","year":"2020","unstructured":"Ortiz Brugu\u00e9s A, Sibaud V, Herbault-Barr\u00e9s B et al (2020) Sicca syndrome induced by immune checkpoint inhibitor therapy: optimal management still pending. Oncologist 25:e391\u2013e395. https:\/\/doi.org\/10.1634\/theoncologist.2019-0467","journal-title":"Oncologist"},{"key":"3565_CR31","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/1759-7714.12216","volume":"6","author":"Y Xu","year":"2015","unstructured":"Xu Y, Fei Y, Zhong W et al (2015) The prevalence and clinical characteristics of primary Sjogren\u2019s syndrome patients with lung cancer: an analysis of ten cases in China and literature review. Thorac Cancer 6:475\u2013479. https:\/\/doi.org\/10.1111\/1759-7714.12216","journal-title":"Thorac Cancer"},{"key":"3565_CR32","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000003540","volume":"95","author":"K-H Yu","year":"2016","unstructured":"Yu K-H, Kuo C-F, Huang LH et al (2016) Cancer risk in patients with inflammatory systemic autoimmune rheumatic diseases. Medicine (Baltimore) 95:e3540. https:\/\/doi.org\/10.1097\/MD.0000000000003540","journal-title":"Medicine (Baltimore)"},{"key":"3565_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2022.103084","volume":"21","author":"H Zhong","year":"2022","unstructured":"Zhong H, Liu S, Wang Y et al (2022) Primary Sj\u00f6gren\u2019s syndrome is associated with increased risk of malignancies besides lymphoma: a systematic review and meta-analysis. Autoimmun Rev 21:103084. https:\/\/doi.org\/10.1016\/j.autrev.2022.103084","journal-title":"Autoimmun Rev"},{"key":"3565_CR34","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.21037\/atm-20-1072","volume":"8","author":"H Yang","year":"2020","unstructured":"Yang H, Yao Z, Zhou X et al (2020) Survival and prognostic factors of lung cancer patients with preexisting connective tissue disease: a retrospective cohort study. Ann Transl Med 8:1415\u20131415. https:\/\/doi.org\/10.21037\/atm-20-1072","journal-title":"Ann Transl Med"},{"key":"3565_CR35","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s00109-014-1130-9","volume":"92","author":"S Lisi","year":"2014","unstructured":"Lisi S, Sisto M, Ribatti D et al (2014) Chronic inflammation enhances NGF-\u03b2\/TrkA system expression via EGFR\/MEK\/ERK pathway activation in Sj\u00f6gren\u2019s syndrome. J Mol Med 92:523\u2013537. https:\/\/doi.org\/10.1007\/s00109-014-1130-9","journal-title":"J Mol Med"},{"key":"3565_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/life13040877","author":"F Ceccarelli","year":"2023","unstructured":"Ceccarelli F, Natalucci F, Picciariello L et al (2023) Rheumatic diseases development in patients treated by anti-PD1 immune checkpoint inhibitors: a single-centre descriptive study. Life. https:\/\/doi.org\/10.3390\/life13040877","journal-title":"Life"},{"key":"3565_CR37","doi-asserted-by":"publisher","DOI":"10.1177\/2040622320976996","author":"S Zhang","year":"2021","unstructured":"Zhang S, Zhou Z, Wang L et al (2021) Rheumatic immune-related adverse events associated with immune checkpoint inhibitors compared with placebo in oncologic patients: a systemic review and meta-analysis. Ther Adv Chronic Dis. https:\/\/doi.org\/10.1177\/2040622320976996","journal-title":"Ther Adv Chronic Dis"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-023-03565-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-023-03565-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-023-03565-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T03:06:15Z","timestamp":1701918375000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-023-03565-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,8]]},"references-count":37,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["3565"],"URL":"https:\/\/doi.org\/10.1007\/s00262-023-03565-6","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,8]]},"assertion":[{"value":"26 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"According to French law, this retrospective study does not require written consent from each patient and obtained a favorable opinion from the local ethics committee (Institutional review board 2019_IRB-MTP_05-22).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}